Goldman Sachs
VNDA icon

Goldman Sachs’s Vanda Pharmaceuticals VNDA Stock Holding History

Goldman Sachs’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-301,200
Closed -$4.58M – 6431
2017
Q4 		$4.58M Buy
301,200
+296,800
+6,745% +$4.4M ﹤0.01% 3077
2017
Q3 		$79K Sell
4,400
-3,700
-46% -$61.9K ﹤0.01% 6140
2017
Q2 		$132K Buy
8,100
+4,800
+145% +$69.2K ﹤0.01% 6009
2017
Q1 		$46K Sell
3,300
-498,500
-99% -$7.1M ﹤0.01% 6310
2016
Q4 		$8M Sell
501,800
-1,300
-0.3% -$20.9K ﹤0.01% 2638
2016
Q3 		$8.37M Buy
503,100
+409,100
+435% +$5.51M ﹤0.01% 2600
2016
Q2 		$1.05M Buy
94,000
+800
+0.9% +$7.75K ﹤0.01% 4140
2016
Q1 		$779K Sell
93,200
-700
-0.7% -$5.75K ﹤0.01% 4313
2015
Q4 		$874K Sell
93,900
-13,400
-12% -$134K ﹤0.01% 4428
2015
Q3 		$1.21M Buy
107,300
+7,800
+8% +$95.4K ﹤0.01% 4285
2015
Q2 		$1.26M Buy
99,500
+97,600
+5,137% +$1.05M ﹤0.01% 4313
2015
Q1 		$18K Sell
1,900
-10,500
-85% -$119K ﹤0.01% 6919
2014
Q4 		$178K Buy
12,400
+6,800
+121% +$80.5K ﹤0.01% 6250
2014
Q3 		$58K Sell
5,600
-216,200
-97% -$2.83M ﹤0.01% 6780
2014
Q2 		$3.59M Buy
221,800
+54,600
+33% +$727K ﹤0.01% 3388
2014
Q1 		$2.72M Sell
167,200
-71,200
-30% -$1.01M ﹤0.01% 3672
2013
Q4 		$2.96M Sell
238,400
-242,600
-50% -$2.44M ﹤0.01% 3646
2013
Q3 		$5.27M Buy
+481,000
New +$5.14M ﹤0.01% 2862

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's VNDA Position: Q1 2026 in Review

Goldman Sachs increased its Vanda Pharmaceuticals (VNDA) stake by 105% in Q1 2026, buying an estimated $3.32M and bringing the position to 838,233 shares worth $5.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3559.

Goldman Sachs first reported a position in VNDA in Q2 2013 and has held it in 52 quarters since. The position peaked at $39.1M in Q1 2015. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Goldman Sachs held 838,233 shares of Vanda Pharmaceuticals worth $5.79M as of Q1 2026.
  • Goldman Sachs bought 429,891 Vanda Pharmaceuticals shares in Q1 2026, an estimated $3.32M.
  • Vanda Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3559 holding.
  • Goldman Sachs first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Vanda Pharmaceuticals position peaked at $39.1M in Q1 2015.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.